NCT02244606Phase 2Completed

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

Study sponsor: Scynexis, Inc. · SCYX

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2016-06Actual
Enrollment · participants27Actual
Source updated2024-06-25Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview